Tirzepatide is a relatively new medication that has attracted significant attention in medical research because of its ability to improve blood sugar control and promote substantial weight loss. Unlike earlier therapies that target only the GLP-1 hormone pathway, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual action appears to enhance its effectiveness in treating metabolic disease. Clinical trials have shown i